{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T05:40:01Z","timestamp":1739338801447,"version":"3.37.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,9,16]],"date-time":"2009-09-16T00:00:00Z","timestamp":1253059200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1007\/s00228-009-0716-6","type":"journal-article","created":{"date-parts":[[2009,9,15]],"date-time":"2009-09-15T07:20:01Z","timestamp":1252999201000},"page":"67-76","source":"Crossref","is-referenced-by-count":13,"title":["Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis"],"prefix":"10.1007","volume":"66","author":[{"given":"Julian","family":"Jenkins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daphne","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanli","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie S.","family":"Kitchen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,9,16]]},"reference":[{"key":"716_CR1","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1182\/blood.V100.10.3457","volume":"100","author":"DJ Kuter","year":"2002","unstructured":"Kuter DJ, Begley CG (2002) Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 100:3457\u20133469","journal-title":"Blood"},{"key":"716_CR2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood.V86.2.419.bloodjournal862419","volume":"86","author":"K Kaushansky","year":"1995","unstructured":"Kaushansky K (1995) Thrombopoietin: the primary regulator of platelet production. Blood 86:419\u2013431","journal-title":"Blood"},{"key":"716_CR3","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.clpt.2004.08.010","volume":"76","author":"B Wang","year":"2004","unstructured":"Wang B, Nichol JL, Sullivan JT (2004) Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharm Ther 76:628\u2013638","journal-title":"Clin Pharm Ther"},{"key":"716_CR4","doi-asserted-by":"crossref","unstructured":"Kuter D, Bussel J, George J et al (2006) Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 48-week update. Blood 108: Abstract 476","DOI":"10.1182\/blood.V108.11.476.476"},{"key":"716_CR5","doi-asserted-by":"crossref","first-page":"2912a","DOI":"10.1182\/blood-2003-05-1669","volume":"104","author":"CL Erickson-Miller","year":"2004","unstructured":"Erickson-Miller CL, Delorme E, Giampa L et al (2004) Biological activity and selectivity for TPO receptor of the orally bioavailable, small molecule TPO receptor agonist, SB-497115. Blood 104:2912a","journal-title":"Blood"},{"key":"716_CR6","doi-asserted-by":"crossref","first-page":"2063a","DOI":"10.1182\/blood.V104.11.2063.2063","volume":"104","author":"T Sellers","year":"2004","unstructured":"Sellers T, Hart T, Semanik M, Murthy K (2004) Pharmacology and safety of SB-497115-GR, an orally active small molecular weight TPO receptor agonist, in chimpanzees, rats and dogs. Blood 104:2063a","journal-title":"Blood"},{"key":"716_CR7","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1182\/blood-2006-11-057968","volume":"109","author":"JM Jenkins","year":"2007","unstructured":"Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, Erickson-Miller CL (2007) Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 109:4739\u20134741","journal-title":"Blood"},{"key":"716_CR8","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","volume":"357","author":"JB Bussel","year":"2007","unstructured":"Bussel JB, Cheng G, Saleh MN et al (2007) Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357:2237\u20132247","journal-title":"N Engl J Med"},{"key":"716_CR9","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1056\/NEJMoa073255","volume":"357","author":"JG McHutchison","year":"2007","unstructured":"McHutchison JG, Dusheiko G, Shiffman ML et al (2007) TPL102357 Study Group Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 357:2227\u20132236","journal-title":"N Engl J Med"},{"key":"716_CR10","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/stemcells.2008-0366","volume":"27","author":"C Erickson-Miller","year":"2008","unstructured":"Erickson-Miller C, Delorme E, Tian SS et al (2008) Preclinical activity of eltrombopag (SB-497115), an oral, non-peptide thrombopoietic growth factor. Stem Cells 27:424\u2013430","journal-title":"Stem Cells"},{"key":"716_CR11","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(02)11203-7","volume":"360","author":"DW Nebert","year":"2002","unstructured":"Nebert DW, Russell DW (2002) Clinical importance of the cytochromes P450. Lancet 360:1155\u20131162","journal-title":"Lancet"},{"key":"716_CR12","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jpba.2004.03.021","volume":"35","author":"MC Jerdi","year":"2004","unstructured":"Jerdi MC, Daali Y, Oestreicher MK, Cherkaoui S, Dayer P (2004) A simplified analytical method for a phenotyping cocktail of major CYP450 biotransformation routes. J Pharm Biomed Anal 35:1203\u20131212","journal-title":"J Pharm Biomed Anal"},{"key":"716_CR13","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/sj.clpt.6100187","volume":"82","author":"JY Ryu","year":"2007","unstructured":"Ryu JY, Song IS, Sunwoo YE, Shon JH, Liu KH, Cha IJ, Shin JG (2007) Development of the \u201cInje cocktail\u201d for high-throughput of five human cytochrome P450 isoforms in vivo. Clin Pharm Ther 82:531\u2013540","journal-title":"Clin Pharm Ther"},{"key":"716_CR14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.clpt.2006.06.005","volume":"80","author":"NK Zgheib","year":"2006","unstructured":"Zgheib NK, Frye RF, Tracy TS, Romkes M, Branch RA (2006) Validation of incorporating flurbiprofen into the Pittsburgh cocktail. Clin Pharmacol Ther 80:257\u2013263","journal-title":"Clin Pharmacol Ther"},{"key":"716_CR15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2125.2006.02781.x","volume":"63","author":"NK Zgheib","year":"2007","unstructured":"Zgheib NK, Frye RF, Tracy TS, Romkes M, Branch RA (2007) Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity. Br J Clin Pharmacol 63:477\u2013487","journal-title":"Br J Clin Pharmacol"},{"key":"716_CR16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0009-9236(03)00050-X","volume":"73","author":"M Christensen","year":"2003","unstructured":"Christensen M, Andersson K, Dal\u00e9n P et al (2003) The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 73:517\u2013528","journal-title":"Clin Pharmacol Ther"},{"key":"716_CR17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2710.2000.00281.x","volume":"25","author":"N Poolsup","year":"2000","unstructured":"Poolsup N, Li Wan Po A, Knight TL (2000) Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther 25:197\u2013220","journal-title":"J Clin Pharm Ther"},{"issue":"Suppl 2","key":"716_CR18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2036.2007.03490.x","volume":"26","author":"PAHM Wijnen","year":"2007","unstructured":"Wijnen PAHM, Op Den Buijsch RAM, Drent M et al (2007) Review article: the prevalence and clinical relevance of cytochrome P450 polymorphisms. Aliment Pharmacol Ther 26(Suppl 2):211\u2013219","journal-title":"Aliment Pharmacol Ther"},{"key":"716_CR19","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0009-9236(03)00229-7","volume":"74","author":"S Chainuvati","year":"2003","unstructured":"Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS Jr (2003) Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the \"Cooperstown 5+1 cocktail\". Clin Pharmacol Ther 74:437\u2013447","journal-title":"Clin Pharmacol Ther"},{"key":"716_CR20","doi-asserted-by":"crossref","first-page":"38617","DOI":"10.1074\/jbc.M505974200","volume":"280","author":"LA McLaughlin","year":"2005","unstructured":"McLaughlin LA, Paine MJ, Kemp CA, Mar\u00e9chal JD, Ward CJ, Stcliffe MJ, Roberts GC, Wolf CR (2005) Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding. J Biol Chem 280:38617\u201338624","journal-title":"J Biol Chem"},{"key":"716_CR21","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1067\/mcp.2000.109519","volume":"68","author":"DS Streetman","year":"2000","unstructured":"Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS Jr (2000) Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the \u2018Cooperstown cocktail\u2019. Clin Pharmacol Ther 68:375\u2013383","journal-title":"Clin Pharmacol Ther"},{"key":"716_CR22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.qai.0000219774.20174.64","volume":"42","author":"RF Yeh","year":"2006","unstructured":"Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ Jr, Klein CE, Rublein JC, Kashuba AD (2006) Lopinavir\/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 42:52\u201360","journal-title":"J Acquir Immune Defic Syndr"},{"key":"716_CR23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00008571-200007000-00001","volume":"10","author":"V Ozdemir","year":"2000","unstructured":"Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10:373\u2013388","journal-title":"Pharmacogenetics"},{"key":"716_CR24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0026-895X(25)09114-X","volume":"36","author":"SA Wrighton","year":"1989","unstructured":"Wrighton SA, Ring BJ, Watkins PB, VandenBranden M (1989) Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol Pharmacol 36:97\u2013105","journal-title":"Mol Pharmacol"},{"key":"716_CR25","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/0140-6736(91)92302-I","volume":"338","author":"JC Kolars","year":"1991","unstructured":"Kolars JC, Awni WM, Merion RM, Watkins PB (1991) First-pass metabolism of cyclosporin by the gut. Lancet 338:1488\u20131490","journal-title":"Lancet"},{"key":"716_CR26","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0022-3565(25)22836-1","volume":"271","author":"KE Thummel","year":"1994","unstructured":"Thummel KE, Shen DD, Podoll TD et al (1994) Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 271:557\u2013566","journal-title":"J Pharmacol Exp Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0716-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-009-0716-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0716-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T04:42:38Z","timestamp":1739335358000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-009-0716-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,16]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["716"],"URL":"https:\/\/doi.org\/10.1007\/s00228-009-0716-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2009,9,16]]}}}